Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

55
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
55
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

34
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
34
Subviral Agents01:29

Subviral Agents

856
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
856

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Losartan alleviated synovitis in patients with metabolic osteoarthritis by down-regulating AT1R to inhibit TGF-β signaling.

Journal of orthopaedic surgery and research·2025
Same author

Cholesterol-27α-hydroxylase inhibitor nilvadipine can effectively treat cholestatic liver injury in adult offspring induced by prenatal dexamethasone exposure.

MedComm·2025
Same author

Identifying autophagy-related mRNAs and potential ceRNA networks in meniscus degeneration based on RNA sequencing and experimental validation.

Heliyon·2024
Same author

Circular RNA Gtdc1 Protects Against Offspring Osteoarthritis Induced by Prenatal Prednisone Exposure by Regulating SRSF1-Fn1 Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Hmga1-overexpressing lentivirus protects against osteoporosis by activating the Wnt/β-catenin pathway in the osteogenic differentiation of BMSCs.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2023
Same author

Inhibition of miR-6215 rescued low subchondral bone mass caused by maternal exposure to dexamethasone in female offspring rats.

Biochemical pharmacology·2023

Related Experiment Video

Updated: Apr 12, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K

[Research on hepatitis C virus entry inhibitor].

Zeng Wenting, Xuemei Lu, Jie Wang

    Bing Du Xue Bao = Chinese Journal of Virology
    |May 23, 2015
    PubMed
    Summary

    Hepatitis C virus (HCV) entry into host cells involves viral proteins and host factors. Targeting these interactions with HCV entry inhibitors offers a promising strategy for effective combination therapy against this global health challenge.

    More Related Videos

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K
    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    24.8K

    Related Experiment Videos

    Last Updated: Apr 12, 2026

    Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
    09:29

    Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

    Published on: October 29, 2015

    31.0K
    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
    11:34

    A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

    Published on: May 10, 2022

    2.8K
    A Protocol for Analyzing Hepatitis C Virus Replication
    13:04

    A Protocol for Analyzing Hepatitis C Virus Replication

    Published on: June 26, 2014

    24.8K

    Area of Science:

    • Virology
    • Immunology
    • Pharmacology

    Context:

    • Hepatitis C virus (HCV) infection is a significant global health issue.
    • No vaccine currently exists for HCV prevention.
    • Combination therapies targeting multiple viral replication steps show improved efficacy.

    Purpose:

    • To review the targets and inhibitors of Hepatitis C virus (HCV) entry into host cells.
    • To provide an overview of research on HCV entry mechanisms and therapeutic strategies since the 1990s.

    Summary:

    • HCV entry involves interactions between viral envelope proteins (E1, E2) and host cell factors (e.g., HS, CD81, SR-BI, OCLD, CLDN, LDLR, DC-SIGN, L-SIGN, TfR1).
    • These viral and host factors represent key targets for developing HCV entry inhibitors.
    • HCV entry inhibitors, particularly in combination therapies, demonstrate significant therapeutic potential.

    Impact:

    • Understanding HCV entry pathways is crucial for developing novel antiviral therapies.
    • Targeting viral entry provides a critical intervention point for HCV treatment.
    • The development of effective HCV entry inhibitors could lead to improved treatment outcomes and disease management.